XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Interest income         $ 102,030 $ 261,269 $ 207,795 $ 444,685  
Principal repayments             $ 17,504 77,753  
Common stock share issued         17,834,023   17,834,023   15,982,472
Accounts receivable balance         $ 18,383,107   $ 18,383,107   $ 19,759,254
Prepaid expenses and other current assets - related party         2,100,450   2,100,450   1,811,911
Basotho Investment Limited [Member]                  
General and administrative expenses             61,800   $ 10,300
Common stock share issued                 120,000
DOC Pharma S.A. 1 [Member]                  
Inventroy purchase         236,590 2,767 425,638 607,984  
Grigorios Siokas [Member]                  
Outstanding principal balance         5,339   5,339   $ 13,257
Foreign curreny translation             420    
Cana Holdings Laboratories Holding Limited [Member]                  
Secured promissory note     $ 4,457,520            
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)            
DOC Pharma S.A. [Member]                  
Interest income             103,584    
Principal repayments             224,220    
Interest repayments             $ 86,841    
Interest rate             5.50%    
Loan term             10 years    
Maturity date             Dec. 01, 2032    
Accounts payable and accrued expenses - related party         112,019   $ 112,019   34,217
Prepaid balance                 4,279,200
Accounts receivable - related party         2,774,038   2,774,038   2,386,721
Prepaid expenses and other current assets - related party         5,482,679   $ 5,482,679   4,347,184
Agreement terminate             Dec. 31, 2025    
Pieces per product             1,000 pieces    
Purchased of additional licenses             $ 525,461    
Loan current portion         431,640   431,640   442,480
Loan non-current portion         3,345,210   3,345,210   3,539,840
Inventroy purchase         136,378 2,120 520,699 193,831  
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600              
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022          
Monthly basis instalments             35,660    
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                  
Inventroy purchase         66,295 190,021 137,027 593,427  
Dimitrios Goulielmos [Member]                  
Outstanding principal balance         10,925   10,925   11,283
Foreign curreny translation             358    
Panagiotis Kozaris [Member]                  
Shares owned         0 51,159      
Prepaid expenses         194,215   194,215   194,215
Maria Kozari [Member]                  
Accounts receivable balance         1,123,835   1,123,835   1,142,402
Net sales         95,195 $ 117,219 181,973 $ 236,205  
George Terzis [Member]                  
Unpaid salaries and bonuses         698,000   698,000   98,000
Kanarogloy & Sia Epe [Member]                  
Accounts payable and accrued expenses - related party         $ 37,292   $ 37,292   $ 85,332